EKF Diagnostics Holdings plc (AIM:EKF)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 111.41M |
| Revenue (ttm) | 50.22M |
| Net Income (ttm) | 6.12M |
| Shares Out | 431.82M |
| EPS (ttm) | 0.01 |
| PE Ratio | 19.10 |
| Forward PE | 17.67 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 87,913 |
| Average Volume | 128,348 |
| Open | 25.90 |
| Previous Close | 25.80 |
| Day's Range | 25.08 - 25.90 |
| 52-Week Range | 18.40 - 32.00 |
| Beta | 0.54 |
| RSI | 50.64 |
| Earnings Date | Mar 23, 2026 |
About EKF Diagnostics Holdings
EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally. The company offers DiaSpect Tm hand-held hemoglobin analyzer; Hemo Control, a hemoglobin and hematocrit analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. It also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Cl... [Read more]
Financial Performance
In 2024, EKF Diagnostics Holdings's revenue was 50.19 million, a decrease of -4.59% compared to the previous year's 52.61 million. Earnings were 6.24 million, an increase of 165.39%.
Financial StatementsNews
EKF Diagnostics Holdings plc (EKDHF) Q2 2025 Earnings Call Transcript
EKF Diagnostics Holdings plc (OTCPK:EKDHF) Q2 2025 Earnings Call September 16, 2025 5:30 AM EDT Company Participants Gavin Jones - CEO & Director Stephen Young - CFO & Executive Director Julian Baines...